Eltrombopag Added to Immunosuppression in Severe Aplastic AnemiaRégis Peffault de Latour, Antonio M. Risitano, Jean-Baptiste Méar et al.|New England Journal of Medicine|2022Cited by 309
Dynamics of Oligoclonal Hematopoiesis in Severe Aplastic Anemia Patients Undergoing Immunosuppressive Treatment: Longitudinal Somatic Mutation Analysis from the EBMT Race TrialD Kaya, Ghulam Mufti, Riley Cook et al.|Blood|2024Cited by 2
Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and EltrombopagDeniz Ece Kaya, Ghulam Mufti, Riley Cook et al.|NEJM Evidence|2026Cited by 2
Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race StudyAntonio M. Risitano, Régis Peffault de Latour, S. Iacobelli et al.|Blood|2024Cited by 1
Deep immune signature of immune-mediated aplastic anemia patients shows distinct subsets of regulatory T cells associated with response to treatment: Results from the phase 3, randomized EBMT race clinical trialSıla Gerlevik, Ghulam Mufti, Giorgio Napolitani et al.|Blood|2025Cited by 0